World's Best Scientists 2026 revealed!
Award Badge
Medicine
New Zealand
2026

D-Index & Metrics

Medicine

D-Index
115
Citations
83172
World Ranking
4425
National Ranking
9

Edward Gane publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Edward Gane sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 726 publications — 83rd percentile

83% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Edward Gane D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Edward Gane sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 115 D-Index — 78th percentile

78% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Medicine in New Zealand Leader Award
  • 2025 - Research.com Medicine in New Zealand Leader Award

Overview

Edward Gane is affiliated with Auckland City Hospital in New Zealand and has a research focus primarily in the field of Medicine, with significant contributions to subfields such as Epidemiology, Hepatology, Oncology, Infectious Diseases, and Immunology.

Their work extensively covers topics related to hepatitis viruses, liver diseases, and cancer immunotherapy. Specifically, their main topics of research include:

  • Hepatitis B Virus Studies
  • Hepatitis C virus research
  • Liver Disease Diagnosis and Treatment
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Cancer Immunotherapy and Biomarkers
  • Hepatitis Viruses Studies and Epidemiology
  • Immunotherapy and Immune Responses

Edward Gane has authored multiple papers, some recent examples include:

  • Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study, 2022, The 'Lancet. Gastroenterology & hepatology
  • Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study, 2020, The Lancet Oncology
  • Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy, 2020, Clinical Microbiology Reviews
  • Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial, 2022, The Lancet Oncology
  • Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial, 2020, Hepatology

Frequent co-authors working with Edward Gane include:

  • Man-Fung Yuen
  • Kosh Agarwal
  • Young-Suk Lim
  • Christian Schwabe
  • María Buti

Their publications often appear in specialized venues related to liver diseases and oncology, with notable frequent publication platforms such as:

  • Journal of Hepatology
  • Hepatology
  • The 'Lancet. Gastroenterology & hepatology
  • Journal of Clinical Oncology
  • Alimentary Pharmacology & Therapeutics

Best Publications

  • Sorafenib in Advanced Hepatocellular Carcinoma

    Josep M. Llovet;Sergio Ricci;Vincenzo Mazzaferro;Philip Hilgard

  • Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.

    S. K. Sarin;M. Kumar;G. K. Lau;Z. Abbas

  • Sofosbuvir for previously untreated chronic hepatitis C infection

    Eric Lawitz;Alessandra Mangia;David Wyles;Maribel Rodriguez-Torres

  • Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study

    Sarah Blach;Stefan Zeuzem;Michael Manns;Ibrahim Altraif

  • Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

    Patrick Marcellin;Edward J Gane;Maria Buti;Nezam H Afdhal

  • Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B

    George K.K. Lau;Teerha Piratvisuth;Kang Xian Luo;Patrick Marcellin

  • Peginterferon alfa-2a in patients with chronic hepatitis C.

    S Zeuzem;S V Feinman;J Rasenack;E J Heathcote

  • Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

    Yun-Fan Liaw;Nancy H. L. Leung;Jia-Horng Kao;Teerha Piratvisuth

  • Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B

    Patrick Marcellin;E Jenny Heathcote;Maria Buti;Ed Gane

  • Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update.

    Yun Fan Liaw;Jia Horng Kao;Teerha Piratvisuth;Henry Lik Yuen Chan

  • Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis

    Merrill D. Benson;Márcia Waddington-Cruz;John L. Berk;Michael Polydefkis

  • Telbivudine versus lamivudine in patients with chronic hepatitis B.

    Ching-Lung Lai;Edward Gane;Yun-Fan Liaw;Chao-Wei Hsu

  • Long-Term Outcome of Hepatitis C Infection after Liver Transplantation

    Edward J. Gane;Bernard C. Portmann;Nikolai V. Naoumov;Heather M. Smith

  • Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

    Graham R. Foster;Nezam Afdhal;Stuart K. Roberts;Norbert Bräu

  • Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C

    Edward J. Gane;Catherine A. Stedman;Robert H. Hyland;Xiao Ding

  • 2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B

    Yun–Fan Liaw;Edward Gane;Nancy Leung;Stefan Zeuzem

  • Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B

    E. Jenny Heathcote;Patrick Marcellin;Maria Buti;Edward Gane

  • Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update.

    Yun-Fan Liaw;Nancy Leung;Richard Guan;George K.K. Lau

  • Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial

    Michael Manns;Didier Samuel;Edward J Gane;David Mutimer

  • Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers

    Alexander J.V. Thompson;Tin Nguyen;David Iser;David Iser;Anna Ayres

Frequent Co-Authors

John G. McHutchison
John G. McHutchison Duke University
Stefan Zeuzem
Stefan Zeuzem Goethe University Frankfurt
Eric Lawitz
Eric Lawitz The University of Texas at Austin
Maria Buti
Maria Buti Instituto de Salud Carlos III
Patrick Marcellin
Patrick Marcellin Université Paris Cité
Ira M. Jacobson
Ira M. Jacobson New York University
Alexander J. Thompson
Alexander J. Thompson Ascension Health
Gregory J. Dore
Gregory J. Dore University of New South Wales
Gail V. Matthews
Gail V. Matthews University of New South Wales
Peter W Angus
Peter W Angus Austin Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA opens up numerous online degree and career paths in healthcare. Advanced nursing roles, for example, are increasingly accessible through flexible online programs tailored for busy professionals and career changers.

If you’re looking to specialize further after becoming a nurse, consider enrolling in a shortest post master's dnp program. These programs help experienced nurses advance quickly to leadership or academic roles.

For those seeking a less traditional pathway, there are also dnp program without clinical hours available. These options can make it easier to balance studies with existing work or life commitments.

Newcomers to nursing can benefit from a lpn program, which provides a fast-track route into the healthcare workforce with practical training.

Additionally, mental health professionals can advance their expertise with specialized online programs, such as the online msn pmhnp programs, designed for those passionate about psychiatric and mental health care.

Best Scientists Citing Edward Gane

Trending Scientists

Recently Published Articles